Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 10/20 | 0.51 |
| ▸ | TPH2 | Q8IWU9 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105458 | 0.83 | KDM4E (0.57) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105713 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HTTKDM4E | |
| SCHEMBL22105408 | 0.77 | BRD4 (0.52) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105568 | 0.75 | TPH1 (0.53) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105569 | 0.75 | KDM4E (0.48) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105565 | 0.74 | PIK3CA (0.38) | ALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL22105376 | 0.72 | TP53 (0.49) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105573 | 0.72 | KDM4E (0.55) | TPH1TPH2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22105360 | 0.72 | PDE5A (0.37) | — | |
| SCHEMBL18036476 | 0.71 | TPH2 (0.67) | TPH1TPH2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| WO-2020120450-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | TPH1 231/4885TPH2 501/4885ALDH1A1 869/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | TPH1 543/4885TPH2 906/4885ALDH1A1 1568/4885 |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | TPH1 335/4885TPH2 664/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.